Is UnitedHealth Stock (UNH) a Buy Ahead of Earnings?

TLDR

• UnitedHealth reports Q4 earnings on January 27 with Wall Street forecasting 69% earnings decline to $2.12 per share
• Shares down 34% over 12 months amid Justice Department probe and Senate investigation into Medicare billing practices
• 16 analysts rate UNH a Buy with average price target of $399.61, implying 12.7% upside from current levels
• Medicare Advantage 2027 rate announcement could deliver 9-10% increases versus Street’s 5% estimate
• Company will rebate 2026 ACA profits to members while facing congressional pressure on affordability

UnitedHealth releases fourth-quarter fiscal 2025 earnings before the opening bell on January 27. Analysts project earnings per share will plunge 69% year-over-year to $2.12.

UnitedHealth Group Incorporated, UNH

Revenue estimates sit at $113.8 billion, marking 13% growth compared to the same quarter last year. The health insurer has missed earnings forecasts in two of its last eight quarters.

Shares climbed 2% to $354.74 on Thursday with volume reaching 7.36 million shares. That’s 5% above typical trading activity.

The stock has dropped 34% over the past year. Multiple headwinds have pressured shares including regulatory scrutiny and rising costs.

A Justice Department investigation into alleged Medicare Advantage billing malpractices continues. Senate investigators recently concluded UnitedHealth employs aggressive tactics to inflate Medicare payments.

President Trump’s healthcare proposal adds another layer of uncertainty. The plan would redirect subsidies straight to consumers, potentially cutting ACA marketplace revenue.

UnitedHealth announced it will rebate 2026 ACA plan profits to customers. The decision helps members but creates near-term earnings pressure.

Wall Street Stands Behind Recovery Thesis

Five analysts reaffirmed Buy ratings heading into the earnings release. Bernstein’s Lance Wilkes selected UnitedHealth as his 2026 top pick.

Wilkes points to gradual improvement in Medicare Advantage and Medicaid businesses. He sees pricing and utilization trends moving in the right direction.

His $444 price target leads the Street. That represents 27.7% upside potential from current prices.

JPMorgan boosted its target to $425 from $310 with an overweight rating. Mizuho lifted its objective to $430 from $300, maintaining an outperform stance.

The consensus rating stands at Strong Buy. Sixteen analysts recommend buying while three suggest holding. The average price target of $399.61 implies 12.7% gains ahead.

Medicare Rate Decision Takes Center Stage

Mizuho’s Ann Hynes highlights the Medicare Advantage 2027 advance notice as a critical catalyst. She forecasts 9-10% rate increases compared to Wall Street’s 5% projection.

Higher reimbursement rates would boost margins for managed care companies. UnitedHealth’s heavy Medicare Advantage exposure positions it to capture outsized benefits.

The rate announcement could mirror the positive impact seen with the 2026 decision. Hynes believes this marks an inflection point for sector recovery.

Options pricing suggests traders expect a 6.31% move in either direction post-earnings. That trails the stock’s average post-earnings swing of 8.84% over the prior four quarters.

Investors will focus on medical cost trends and medical cost ratio beyond headline numbers. Rising medical expenses and elevated cost ratios threaten to squeeze margins.

Congressional leaders grilled UnitedHealth executives on healthcare affordability recently. The increased political scrutiny raises execution risks and public relations challenges.

Institutional investors control 87.86% of outstanding shares. Brighton Jones LLC increased its position by 176.2% during the fourth quarter.

Analysts warn that cost pressures remain a red flag. Some recommend waiting for the January 27 earnings report and rate guidance before adding positions.

The post Is UnitedHealth Stock (UNH) a Buy Ahead of Earnings? appeared first on Blockonomi.